Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Bristol-Myers Squibb Co    BMY

News SummaryMost relevantAll newsSector newsTweets 

Bristol-Myers Gets SEC Subpoena In Foreign Bribery Probe

share with twitter share with LinkedIn share with facebook
share via e-mail
04/26/2012 | 07:01pm CET
   By Peter Loftus 

Drug maker Bristol-Myers Squibb Co. (>> Bristol Myers Squibb Co.) said it has received a subpoena from the U.S. Securities and Exchange Commission as part of an investigation into bribery overseas.

Bristol-Myers said the subpoena received in March seeks information related to sales and marketing practices in "various countries."

The New York-based company said in a quarterly report filed Thursday with the SEC that it was cooperating with the government. A spokeswoman declined comment beyond the information in Thursday's SEC filing.

Bristol-Myers, which sells the anti-clotting drug Plavix, previously disclosed that the SEC was investigating the activities of the company's units in Germany, concerning potential violations of the U.S. Foreign Corrupt Practices Act, or FCPA.

U.S. authorities in recent years have stepped up enforcement of the FCPA, which bars U.S. companies from bribing foreign officials to obtain or retain business. Multinational drug and medical-device makers based in the U.S. have been among the targets of enforcement.

Last year, Johnson & Johnson (>> Johnson & Johnson) agreed to pay nearly $80 million to resolve allegations that it paid bribes to doctors in three European countries, as well as kickbacks to Iraq to illegally obtain business under former leader Saddam Hussein.

Other drug makers--including Pfizer Inc. (>> Pfizer Inc.), Merck & Co. (>> Merck & Co., Inc.) and Eli Lilly & Co. (>> Eli Lilly & Co.)--also have been the subjects of federal inquiries regarding the FCPA.

-By Peter Loftus, Dow Jones Newswires; +1-215-982-5581; peter.loftus@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
01/14 BRISTOL MYERS SQUIBB : Founders Financial Securities adds Bristol-Myers Squibb C..
01/12 BRISTOL MYERS SQUIBB : Janssen Enters Immunotherapy Clinical Collaboration with ..
01/12 BRISTOL MYERS SQUIBB : Studies from Bristol-Myers Squibb Have Provided New Infor..
01/12 BRISTOL MYERS SQUIBB : to Present at J.P. Morgan Healthcare Conference
01/12 BRISTOL MYERS SQUIBB : Researchers from Bristol-Myers Squibb Discuss Findings in..
01/12 BRISTOL MYERS SQUIBB : Details Findings in Medicinal Chemistry (Difluorocyclobut..
01/12 BRISTOL MYERS SQUIBB : Data on Biosensing Reported by Researchers at Bristol-Mye..
01/12 BRISTOL MYERS SQUIBB : Announces Immunotherapy Clinical Collaboration with Janss..
01/12 BRISTOL MYERS SQUIBB : Findings from Bristol-Myers Squibb Provides New Data on H..
01/12 BRISTOL MYERS SQUIBB : Investigators from Bristol-Myers Squibb Release New Data ..
More news
Sector news : Pharmaceuticals - NEC
01/18DJCSL : Expects Higher Profits On Strong Immunoglobulin Sales -- Update
01/18DJCSL : Expects Higher 1st Half Profits On Strong Immunoglobulin Sales
01/18DJMALLINCKRODT : to Pay $100 Million to Settle Antitrust Allegations on Unlawful D..
01/18DJELI LILLY AND : to Buy Migraine Drug Developer CoLucid Pharmaceuticals
01/18 Drugmakers in Davos shift focus to chronic diseases of poor
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
01/18 3 COMPANIES WITH RECENT DIVIDEND INC : Review Using Dividend Safety Model - Janu..
01/18 Astra's Mystic Mystery And Other Surprises In Store
01/13 BIOTECHS : What The 'Trump Dump' And CVS's EpiPen Move May Mean
01/12 Merck gets upgrades on leadership in drug/chemo combo race
01/11 Allergan CEO also has a Twitter account
Financials ($)
Sales 2016 19 320 M
EBIT 2016 5 355 M
Net income 2016 4 639 M
Debt 2016 175 M
Yield 2016 2,78%
P/E ratio 2016 20,40
P/E ratio 2017 20,00
EV / Sales 2016 4,88x
EV / Sales 2017 4,67x
Capitalization 94 057 M
More Financials
Duration : Period :
Bristol-Myers Squibb Co Technical Analysis Chart | BMY | US1101221083 | 4-Traders
Full-screen chart
Technical analysis trends BRISTOL-MYERS SQU...
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 62,5 $
Spread / Average Target 11%
Consensus details
EPS Revisions
More Estimates Revisions
Giovanni Caforio Chief Executive Officer & Director
Lamberto Andreotti Chairman
Charles A. Bancroft Chief Financial Officer & Executive Vice President
Francis M. Cuss Chief Scientific Officer & Executive VP
Paul von Autenried Chief Information Officer & Senior Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON-0.30%312 507
ROCHE HOLDING LTD.1.29%200 476
PFIZER INC.-1.29%194 551
NOVARTIS AG-2.70%185 185
MERCK & CO., INC.4.43%169 509
More Results